You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 247 No. 4, January 22, 1982 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL NOTES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Nafcillin-Tolerant Staphylococcus epidermidis Endocarditis

COL James D. Arthur, MC; COL James W. Bass, MC; MAJ John F. Keiser, PhD, MC; LTC Lewis B. Harden, MC; Scott L. Brown

JAMA. 1982;247(4):487-488.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RESISTANCE of Staphylococcus aureus and S epidermidis organisms to penicillin is known to be mediated by several different mechanisms. Resistance due to production of β-lactamase (penicillinase) resulting in penicillin inactivation was recognized with S aureus in the early 1960s.1 "Intrinsic" resistance to the penicillinase-resistant penicillins (PRPs) has been observed in both S aureus and S epidermidis for more than ten years.2 Recently, strains of S aureus described as "tolerant" to PRPs have been reported.3 This tolerance is manifested by a wide disparity between the concentration of penicillin required to inhibit growth of the organism and that required for killing it. Routine antibiotic sensitivity testing shows these strains to be sensitive to PRPs. The minimal inhibitory concentration (MIC) is well within the therapeutic range of these drugs, but the minimal bactericidal concentration (MBC) is 32 times the MIC or greater, indicating a required therapeutic level not practically achievable . . . [Full Text PDF of this Article]


Author Affiliations

USA; USA; USA; USA

From the Departments of Pediatrics (Drs Arthur and Harden) and Pathology (Dr Keiser and Mr Brown), Walter Reed Army Medical Center, Washington, DC, and the Department of Pediatrics (Dr Bass), Uniformed Services University of Health Sciences, Bethesda, Md.


Footnotes

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.